PBT2

PBT2 is an experimental drug candidate. It is a second-generation 8-hydroxyquinoline analog intended to be a successor to clioquinol and a potential treatment of Alzheimer's disease and Huntington disease. PBT2 is an experimental drug candidate. It is a second-generation 8-hydroxyquinoline analog intended to be a successor to clioquinol and a potential treatment of Alzheimer's disease and Huntington disease. PBT2 was the subject of three phase II clinical trials for Alzheimer's disease (‘EURO’), ‘IMAGINE’ & ‘IMAGINE EXTENSION’) and one for Huntington's disease (‘REACH2HD’) trial. The cognition efficacy results for Alzheimer's disease were mixed. The EURO trial showed some improvements in cognitive functions, in particular executive function domains, while the IMAGINE study did not. Although there is no evidence that PBT2 is of any benefit in Alzheimer's dementia, the number of subjects treated with PBT2 for AD in Phase II placebo controlled trials (N~76) is limited and the trials were not powered to detect cognitive outcomes. In the Phase II PBT2 trial in Huntington disease, whilst the overall cognitive composite measured was not improved, an executive function domain within the composite was significantly improved.